Skip to main content
SpringerLink
Log in

Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia? Reply to Sánchez‑Hernández and Wägner [letter]

  • Letter
  • Published:
Diabetologia Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abbreviations

ASCVD:

Atherosclerotic cardiovascular disease

FH:

Familial hypercholesterolaemia

LLT:

Lipid-lowering therapy

References

  1. Sánchez-Hernández RM, Wägner AM (2024) Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia? Diabetologia 67:952–953. https://doi.org/10.1007/s00125-024-06115-6

  2. Corpeleijn WE, de Waal WJ, Schipper HS, Wiegman A (2024) Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia. Diabetologia 67:19–26. https://doi.org/10.1007/s00125-023-06041-z

    Article  PubMed  Google Scholar 

  3. Wiegman A, Hutten BA, de Groot E et al (2004) Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292(3):331–337. https://doi.org/10.1001/jama.292.3.331

    Article  CAS  PubMed  Google Scholar 

  4. Santos RD, Ruzza A, Hovingh GK et al (2020) Evolocumab in pediatric heterozygous familial hypercholesterolemia. N Engl J Med 383(14):1317–1327. https://doi.org/10.1056/NEJMoa2019910

  5. Santos RD, Wiegman A, Caprio S et al (2024) Alirocumab in pediatric patients with heterozygous familial hypercholesterolemia. JAMA Pediatr 178(3):283–293. https://doi.org/10.1001/jamapediatrics.2023.6477

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands

    Willemijn E. Corpeleijn & Albert Wiegman

  2. Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands

    Willemijn E. Corpeleijn & Albert Wiegman

  3. Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam University Medical Centers, location AMC, Amsterdam, the Netherlands

    Willemijn E. Corpeleijn & Albert Wiegman

  4. Diabetes Centraal, Children’s Diabetic Centre, St Antonius Hospital, Utrecht, the Netherlands

    Wouter J. de Waal

  5. Department of Pediatric Cardiology, Erasmus Medical Centre - Sophia Children’s Hospital, Rotterdam, the Netherlands

    Henk S. Schipper

Authors
  1. Willemijn E. Corpeleijn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wouter J. de Waal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henk S. Schipper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Albert Wiegman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Albert Wiegman.

Ethics declarations

Authors’ relationships and activities

AW reports research support for pharmaceutical trials of lipid modifcation agents from Amgen, Esperion, Novartis, Regeneron, Sanofi, Silence Therapeutic and Ultragenyx and is a member of the safety board at Chiesi and chair of the ORION 13 and 16 steering committee at Novartis. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work

Contribution statement

All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Corpeleijn, W.E., de Waal, W.J., Schipper, H.S. et al. Should children with type 1 diabetes really receive statin treatment using the same criteria as for children with familial hypercholesterolaemia? Reply to Sánchez‑Hernández and Wägner [letter]. Diabetologia (2024). https://doi.org/10.1007/s00125-024-06174-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00125-024-06174-9

Keywords

Search

Navigation